Intracellular calcium concentration increase inhibitors

Details Intracellular calcium concentration increase inhibitors Intracellular calcium concentration increase inhibitors

2007-05-15

2007-05-15

Gaeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Boron containing doai

C556S007000

Reexamination Certificate

active

10492150

ABSTRACT:
An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

REFERENCES:
patent: 3397228 (1968-08-01), Brownstein
patent: 0059880 (2000-10-01), None
patent: 0127107 (2001-04-01), None
patent: 0238140 (2002-06-01), None
Holzapfel et al., 1965, CAS: 63:89008.
Lapkin et al., 1963, CAS: 58:27392.
Dobrydneva, Yuliya et al., “2-aminoethoxydiphenyl borate directly inhibits store-operated calcium entry channels in human platelets,” Molecular Pharmacology, Sep. 2001, vol. 60, No. 3, pp. 541-552.
Kukkonen, J.P. et al., “2-aminoethoxydiphenyl borate reveals heterogeneity in receptor-activated Ca2+ discharge and store-operated Ca2+ influx,” Cell Calcium, Aug. 2001, vol. 30, No. 2, pp. 117-129.
Missiaen, L. et al, 2-Aminoethoxydiphenyl borate affects the inositol 1,4,5-trisphosphate receptor, the intracellular Ca2+ pump and the non-specific Ca2+ leak from the non-mitochondrial Ca2+ stores in permeabilized A7r5 cells,' Cell Calcium, Feb. 2001, vol. 29, No. 2, pp. 111-116.
Wu, Jie et al., “2-Aminoethoxydiphenyl borate modulates kinetics of intracellular Ca2+ signals mediated by inositol 1 4,5-trisphosphate-sensitive Ca2+ stores in single pancreatic acinar cells of mouse,” Molecular Pharmacology, 2000, vol. 58, No. 6, pp. 1368-1374.
Maruyama, Takayuki et al., “2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release,” Journal of Biochemistry (Tokyo), 1997, vol. 122, No. 3, pp. 498-505.
Reilly, T.M. et al., “Effect of thrombin inhibitors on platelet functions: aomparative analysis of DuP 714 and hirudin,” Blood Coagulation & Febrinolysis, 1992, vol. 3, No. 5, pp. 513-517.
Chiu, Anrew T. et al., “Inhibition of thrombin-platelet reactions by DuP714,” Biochemical and Biophysical Research Communications, 1991, vol. 179, No. 3, pp. 1500-1508.
International Search Report mailed Jan. 28, 2003.
Brief Report—“Capacitative Calcium Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice”—Malcolm A. Leissring et al; The Rockefeller University Press, 0021-9525/2000/05/793/5, the Journal of Cell Biology, vol. 149, No. 4, May 15, 2000 793-797.
“Presenilin-Mediated Modulation of Capacitative Calcium Entry”—Andrew S. Yoo et al—Neuron, vol. 27, 561-572, Sep. 2000, copyright 2000 by Cell Press.

Affiliated with

Also associated with

Rating

Intracellular calcium concentration increase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intracellular calcium concentration increase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intracellular calcium concentration increase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3738738